openPR Logo
Press release

Sepsis Pipeline Forecast 2024: FDA Approvals, Therapies by DelveInsight | Roche, Pfizer Inc., GSK Plc, Viatris, Mylan, AbbVie, Allergan Pharma, Asahi Kasei Crp., RegeneRx

07-10-2024 04:56 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Sepsis Pipeline Forecast 2024: FDA Approvals, Therapies

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Sepsis pipeline constitutes 25+ key companies continuously working towards developing 30+ Sepsis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Sepsis Pipeline Insight, 2024 []" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sepsis Market.

The Sepsis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Sepsis Pipeline Report:

Companies across the globe are diligently working toward developing novel Sepsis treatment therapies with a considerable amount of success over the years.

Sepsis companies working in the treatment market are Fe Pharmaceuticals, Revagenix, Northern Therapeutics, Recce Pharmaceuticals, Artcline GmbH, Inotrem, Shionogi, SciClone Pharmaceuticals, and others, are developing therapies for the Sepsis treatment

Emerging Sepsis therapies in the different phases of clinical trials are- FEP-100, Research programme, GEM00220, RECCE 327, ARTICE therapy, Nangibotide, Cefiderocol, Thymosin alpha, and others are expected to have a significant impact on the Sepsis market in the coming years.

In May 2024, A clinical trial funded by the US National Institutes of Health (NIH) suggests that intravenous acetaminophen may benefit sepsis patients. In this mid-stage trial, 447 adult sepsis patients with respiratory or circulatory organ dysfunction were enrolled. Conducted from October 2021 to April 2023, the study involved participants admitted to 40 academic hospitals across the US. They were randomly assigned to receive either intravenous acetaminophen or a placebo every six hours for five days. The primary focus was on the number of patients surviving without the need for organ support, such as mechanical ventilation or kidney failure treatment.

In April 2024, Enlivex Therapeutics has announced positive top-line safety and efficacy results from its Phase II clinical trial of Allocetra, an off-the-shelf cell therapy, for sepsis treatment. This placebo-controlled, randomized trial aims to identify the optimal dose of Allocetra when combined with the standard of care for sepsis caused by various infections. The study targeted patients with sepsis linked to pneumonia, biliary, urinary tract, or peritoneal infections.

In January 2024, Matisse Pharmaceuticals has announced positive top-line results from the HistoSeps trial, which aimed to assess the tolerability, safety, and pharmacokinetics of M6229 for sepsis treatment. Conducted at Amsterdam University Medical Center, this first-in-human trial involved ten critically ill patients and achieved its primary objectives. The trial showed favorable tolerability and safety, as well as nearly dose-proportional pharmacokinetics for six-hour intravenous (IV) administration of M6229 in these patients.

Sepsis Overview

Sepsis is a severe medical condition triggered by the body's overwhelming response to infection. It can lead to tissue damage, organ failure, and potentially death if not treated promptly.

Get a Free Sample PDF Report to know more about Sepsis Pipeline Therapeutic Assessment- []

Emerging Sepsis Drugs Under Different Phases of Clinical Development Include:

FEP-100: Fe Pharmaceuticals

Research programme: Revagenix

GEM00220: Northern Therapeutics

RECCE 327: Recce Pharmaceuticals

ARTICE therapy: Artcline GmbH

Nangibotide: Inotrem

Cefiderocol: Shionogi

Thymosin alpha: SciClone Pharmaceuticals

Sepsis Route of Administration

Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as






Sepsis Molecule Type

Sepsis Products have been categorized under various Molecule types, such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody



Gene therapy

Sepsis Pipeline Therapeutics Assessment

Sepsis Assessment by Product Type

Sepsis By Stage and Product Type

Sepsis Assessment by Route of Administration

Sepsis By Stage and Route of Administration

Sepsis Assessment by Molecule Type

Sepsis by Stage and Molecule Type

DelveInsight's Sepsis Report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Further Sepsis product details are provided in the report. Download the Sepsis pipeline report to learn more about the emerging Sepsis therapies []

Some of the key companies in the Sepsis Therapeutics Market include:

Key companies developing therapies for Sepsis are - F . Hoffmann-La Roche Ltd, Pfizer Inc., GSK Plc, Viatris Inc. (Mylan Inc.), AbbVie Inc (Allergan Pharmaceuticals Private Limited), Asahi Kasei Corporation, RegeneRx, Inotrem SAEndacea Inc., Adrenomed AG, and others.

Sepsis Pipeline Analysis:

The Sepsis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Sepsis with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sepsis Treatment.

Sepsis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Sepsis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sepsis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Sepsis drugs and therapies []

Sepsis Pipeline Market Drivers

Increase in awareness of Sepsis, increase in the Research and Development activities are some of the important factors that are fueling the Sepsis Market.

Sepsis Pipeline Market Barriers

However, side effects associated with the treatment, economic burden associated with the disease and other factors are creating obstacles in the Sepsis Market growth.

Scope of Sepsis Pipeline Drug Insight

Coverage: Global

Key Sepsis Companies: Fe Pharmaceuticals, Revagenix, Northern Therapeutics, Recce Pharmaceuticals, Artcline GmbH, Inotrem, Shionogi, SciClone Pharmaceuticals, and others

Key Sepsis Therapies: FEP-100, Research programme, GEM00220, RECCE 327, ARTICE therapy, Nangibotide, Cefiderocol, Thymosin alpha, and others

Sepsis Therapeutic Assessment: Sepsis current marketed and Sepsis emerging therapies

Sepsis Market Dynamics: Sepsis market drivers and Sepsis market barriers

Request for Sample PDF Report for Sepsis Pipeline Assessment and clinical trials []

Table of Contents

1. Sepsis Report Introduction

2. Sepsis Executive Summary

3. Sepsis Overview

4. Sepsis- Analytical Perspective In-depth Commercial Assessment

5. Sepsis Pipeline Therapeutics

6. Sepsis Late Stage Products (Phase II/III)

7. Sepsis Mid Stage Products (Phase II)

8. Sepsis Early Stage Products (Phase I)

9. Sepsis Preclinical Stage Products

10. Sepsis Therapeutics Assessment

11. Sepsis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sepsis Key Companies

14. Sepsis Key Products

15. Sepsis Unmet Needs

16 . Sepsis Market Drivers and Barriers

17. Sepsis Future Perspectives and Conclusion

18. Sepsis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email []
Phone: +14699457679
City: Boston
State: MA
Country: United States

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Sepsis Pipeline Forecast 2024: FDA Approvals, Therapies by DelveInsight | Roche, Pfizer Inc., GSK Plc, Viatris, Mylan, AbbVie, Allergan Pharma, Asahi Kasei Crp., RegeneRx here

News-ID: 3575003 • Views:

More Releases from ABNewswire

Local Homeowners Trust Shield Roofing Services for Top-Quality Roofing Solutions
Local Homeowners Trust Shield Roofing Services for Top-Quality Roofing Solutions
This trust is not easily earned; it comes from years of delivering high-quality, reliable services that meet the diverse needs of homeowners. Whether dealing with the aftermath of a storm or planning a new roof installation, Shield Roofing Services is the go-to choice for residents. Shield Roofing Services has built a solid reputation in the community for providing exceptional roofing solutions. This trust is not easily earned; it comes from years
Klondike Solitaire Turn One - How to Play Guide by Solitaireee
Klondike Solitaire Turn One - How to Play Guide by Solitaireee
Image: Welcome to your ultimate guide on playing Klondike Solitaire Turn One []! This classic card game has captivated players for generations, offering a perfect blend of strategy, patience, and skill. Whether you're a seasoned solitaire enthusiast or a complete beginner, this guide will walk you through the basics and offer winning strategies to enhance your gameplay. Understanding the Objective The main objective of Klondike Solitaire Turn One [] is to
Integris Roofing Introduces Comprehensive Roof Repair Services for All Roof Types
Integris Roofing Introduces Comprehensive Roof Repair Services for All Roof Type …
Integris Roofing, a leader in the roofing industry, is excited to announce the launch of its comprehensive roof repair [,roof%20repair,-.%20We%20work%20on] services tailored for all roof types. This expansion marks a significant step in providing top-tier solutions to homeowners and businesses facing various roofing issues. Known for its commitment to quality and customer satisfaction, Integris Roofing is poised to address the diverse needs of its clientele with unmatched expertise and dedication. Addressing
Manassas Plumbing Pros Launches Innovative Eco-Friendly Plumbing Solutions
Manassas Plumbing Pros Launches Innovative Eco-Friendly Plumbing Solutions
In a significant stride towards environmental sustainability, Manassas Plumbing Pros has introduced a range of innovative eco-friendly plumbing [,Plumbing,-Solutions%20You%20Need] solutions. Recognized for their commitment to excellence and customer satisfaction, this plumbing company is set to revolutionize the industry with their green initiatives. Homeowners and businesses alike are expected to benefit from these cutting-edge technologies and practices, which aim to conserve water, reduce energy consumption, and minimize environmental impact. The introduction of

All 5 Releases

More Releases for Sepsis

Global Sepsis Diagnostics Market to witness Significant Growth Given the Increas …
Inkwood Research anticipates that the Global Sepsis Diagnostics Market is evaluated to record a CAGR of 8.06% in terms of revenue during the forecasting years of 2021-2028. "Browse 55 Market Data Tables and 48 Figures spread over 220 Pages, along with an in-depth TOC on the Global Sepsis Diagnostics Market Forecast 2021-2028." REQUEST FREE SAMPLE LINK - Sepsis develops due to the body's response to pathogenic microorganisms, within the blood. The increasing
Sepsis Diagnostics Market 2021 | Increasing Neonatal Umbilical Cord Sepsis Cases …
Sepsis Diagnostics Market 2021 Overview: Sepsis Alliance, a non-profit group, sponsored "It's About TIME" in June 2018, a national campaign to increase awareness about rapid diagnosis and illness care. It is expected that such initiatives by different organizations will raise awareness of the disease and increase the demand for its diagnostic solutions. The latest research report, titled “Sepsis Diagnostics Market” Added by Straits Research, provides the reader with a comprehensive overview of the
04-22-2021 | Health & Medicine
Sepsis Diagnostics Spurring Heightened R&D to Introduce New Solutions to Prevent …
Fact.MR’s revised sepsis diagnostics market study forecasts a healthy growth trajectory for FY 2021-22 and beyond, with the market expected to increase at a CAGR worth around 8% through 2031. Growth prospects were further underpinned amidst the coronavirus pandemic, attributed to the onset of pneumonia-induced sepsis and consequent fatalities. Click HERE to Get Synopsis of the Report- According to the report, the market is expected to yield high short-term gains, generating
Sepsis Diagnostics Market
Sepsis Diagnostics Market by Type, Top Key Players, Size, Share, Growth, Trends - Opportunity, Analysis, Forecast 2024 Sepsis Diagnostics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Sepsis Diagnostics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Sepsis Diagnostics manufacturers and is a valuable source of guidance and
Sepsis Diagnostics Market: Opportunities & Challenges
The Global Sepsis Diagnostics Market is estimated to reach USD 613.9 million by 2023 from USD 396.6 billion in 2018, at a CAGR of 9.1% from 2018 to 2023. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis across the globe. Factors such as the rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and the commercialization and availability of a wide variety
Sepsis Diagnostics
Sepsis Diagnostics Market describes its growth, size, share, Forecast and trends to 2025 Sepsis Diagnostics Market Production and Demand Analysis 2019 to 2025 Sepsis Diagnostics Market 2019 Manufacturing Analysis and Development Forecast 2025 Sepsis Diagnostics Market 2019: Recent Study Including Growth Factors, Regional Drivers, Forecast 2025 Sepsis Diagnostics Market to Insight By 2025: Top Key Vendors Sepsis is a three-staged syndrome; it starts with systemic infections leading to severe sepsis and ultimately causing sepsis shock,